Biocon Limited
Valuation (68/100) does the heavy lifting; financial trend (12/100) is the drag.
ExpensiveSolvency riskStocksWizard rates Biocon Limited a Sell, scoring 37/100 on our blended model. We put fair value near ₹698.7; at ₹390.65 that leaves roughly 79% upside, so the stock screens undervalued by 79%. On 148.1x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 11% below its 52-week high of ₹440.7 and 15% above the low of ₹338.5. Financial health scores 31/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹414.05 implies about 6% upside across 20 analysts. It clears 4 of 14 investability checks, with durability 27, valuation 35 and momentum 30 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹558.96. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-09-1252-week range
-11.36% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell37Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 1.1%
- Pass: Low debt (D/E < 0.5): 0.42x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 2%
- Fail: Earnings growing: -73%
- Fail: Net margin ≥ 10%: 2.3%
- Fail: Current ratio > 1.5: 1.22
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- Pass: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.25
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter54.1%
- Institutions26.4%
- Public & other19.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Opportunities
- Trades ~79% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (1.1%).
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About Biocon Limited
Biocon Limited manufactures and sells biotechnology products and research services across India, the United States, Ireland, the European Union, and other international markets. The company operates through Generics, Biosimilars, and Research segments, offering generic formulations and active pharmaceutical ingredients in cardiovascular, anti-diabetic, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressant, and specialty molecule categories, as well as biosimilar products.
Biocon Limited — frequently asked questions
Is Biocon Limited a buy, hold or sell?
StocksWizard currently rates Biocon Limited (BIOCON) a Sell, based on a blended score of 37/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Biocon Limited's fair value?
Our blended DCF and relative-valuation model estimates Biocon Limited's fair value at about ₹698.7, versus a current price of ₹390.65 — roughly 79% upside. On that basis the stock looks undervalued by 79%.
Is Biocon Limited financially healthy?
Biocon Limited scores 31/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Biocon Limited's share price performed?
Biocon Limited is up 7% over the past year and down 6% over three months, and last traded at ₹390.65. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.